Pathway option matrix by target market
Practical, reviewable, and ready for the owner who needs to act, approve, or respond.
“
Strategy locked
Pathway Map
StatusStrategy locked
Our craft
Built around real regulatory affairs practice.
Service Detail
Choose the right regulatory route before major spend.
Choose the right pathway before you spend on dossiers, studies, or local filings. PharmaRevix maps options, risks, data gaps, and authority expectations so teams can move with confidence.
You are entering a new market and need route clarity
You need to compare EU, US, Canada, ANZ, GCC, Switzerland, South Africa, Latam, and ROW options
You have study, biowaiver, or bridging questions
You need leadership-ready regulatory rationale
Deliverables
Practical outputs your team can use immediately.
Regulatory risk and data-gap assessment
Practical, reviewable, and ready for the owner who needs to act, approve, or respond.
Biowaiver or bioequivalence strategy memo
Practical, reviewable, and ready for the owner who needs to act, approve, or respond.
Authority interaction recommendation
Practical, reviewable, and ready for the owner who needs to act, approve, or respond.
Submission sequence and timing plan
Practical, reviewable, and ready for the owner who needs to act, approve, or respond.
Executive-ready decision pack
Practical, reviewable, and ready for the owner who needs to act, approve, or respond.
Workflow
A clear sequence from assessment to handoff.
01
Assess
Assess product class, formulation, evidence, and target markets
02
Plan
Compare possible routes with data, cost, and timing implications
03
Execute
Define the recommended pathway and risk controls
04
Maintain
Translate the strategy into submission-ready work packages
Proof Package
Every engagement leaves an evidence trail.
The work is designed for real review: authority questions, partner due diligence, quality audits, and internal leadership updates.
EU / UK / USROW planSenior-led
Product and market pathway assessment
Captured with owners, assumptions, decision rationale, and next actions so the work can continue smoothly.
Biowaiver, bridging, and bioequivalence strategy
Captured with owners, assumptions, decision rationale, and next actions so the work can continue smoothly.
Submission sequence and dependency planning
Captured with owners, assumptions, decision rationale, and next actions so the work can continue smoothly.
Regulatory risk register with mitigation actions
Captured with owners, assumptions, decision rationale, and next actions so the work can continue smoothly.
Related Services
Connect this work with adjacent regulatory and safety needs.
Global Expansion
Leverage existing EU or US approvals and adapt the dossier intelligently for each country. PharmaRevix helps you prioritize markets, coordinate local representatives, and keep submissions moving.
Explore serviceMarketing Authorizations
PharmaRevix supports new applications, variations, renewals, annual reports, eCTD publishing, and MAH-related regulatory operations across key markets.
Explore serviceTechnical Documentation
PharmaRevix prepares CMC content, clinical and non-clinical overviews, risk assessments, and deficiency responses aligned to current ICH and regional expectations.
Explore serviceFAQ
Common questions about Regulatory Strategy.
Short answers for teams deciding whether this is the right next step.
Ask us anythingRegulatory strategy defines the right approval pathway before dossier, study, or local filing spend begins. PharmaRevix maps options, risks, data gaps, and authority expectations so teams can move with confidence.
The right timing depends on product stage, target markets, and regulatory commitments. PharmaRevix usually starts with a focused review and then sets a workplan with owners, dates, and evidence expectations.
Yes. PharmaRevix can scope this as a standalone workstream or connect it with adjacent regulatory affairs, pharmacovigilance, QMS, and submission activities.
Free 30-minute consultation
Need regulatory strategy support?
Talk with PharmaRevix about scope, timelines, and the cleanest next step for your market or safety obligation.